---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-003635"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T12:41:40.638480+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Regains Full Rights to ARO-PNPLA3 After Janssen Terminates Collaboration

## Summary
- Janssen terminated the Research Collaboration and Option Agreement with Arrowhead effective April 7, 2023.
- Arrowhead regains all rights and licenses to ARO-PNPLA3 (formerly JNJ-75220795), a NASH candidate.
- Phase 1 data showed up to 40% mean reduction in liver fat in PNPLA3 I148M homozygotes after a single dose.
- No serious adverse events reported; safety profile encouraging with mostly mild AEs.
- Arrowhead plans to design a Phase 2 study and assess options for communicating full Phase 1 results.

## SEC filing metadata
- accession: 0001628280-23-003635
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023003635/0001628280-23-003635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023003635/arwr-20230210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-003635
- JSON: https://secwatch.observer/filing/0001628280-23-003635.json
- Plain text: https://secwatch.observer/filing/0001628280-23-003635.txt

## Key facts
- Material Agreements
  ARROWHEAD PHARMACEUTICALS, INC. terminated Collaboration Agreement with Janssen Pharmaceuticals, Inc. (effective 2023-04-07).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Janssen Pharmaceuticals, Inc.
  - Effective: 2023-04-07
  source text: On February 10, 2023, Arrowhead Pharmaceuticals, Inc. (the “Company”) received notice from Janssen Pharmaceuticals, Inc. (“Janssen”) that Janssen has elected to terminate the Research Collaboration and Option Agreement between the Company and Janssen, dated October 3, 2018 (as amended by Amendment No. 1 to the Research Collaboration and Option Agreement between the Company and Janssen, dated as of November 14, 2019, the “Collaboration Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023003635/0001628280-23-003635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.